NICE Nod To Alexion’s Soliris May Mean Move Away From Cost Emphasis
This article was originally published in The Pink Sheet Daily
Executive Summary
Despite the drug’s high price and significant budget impact, NICE has recommended Alexion’s Soliris for aHUS, suggesting the U.K. health technology assessment agency is easing its focus on cost.